Management of Chemotherapy-Induced Nausea and Vomiting

New Agents and New Uses of Current Agents

  • Rudolph M. Navari

Table of contents

  1. Front Matter
    Pages i-viii
  2. Rudolph M. Navari
    Pages 1-3
  3. Roy Chen, Kathy Deng, Harry Raftopoulos
    Pages 45-62
  4. Lee Schwartzberg
    Pages 63-84
  5. Bernardo Leon Rapoport
    Pages 85-105
  6. Thomas J. Guttuso Jr.
    Pages 121-133
  7. Rudolph M. Navari
    Pages 157-162
  8. Rudolph M. Navari
    Pages 163-176
  9. Rudolph M. Navari
    Pages 177-178
  10. Rudolph M. Navari
    Pages 179-181

About this book

Introduction

This book provides a comprehensive review of new agents, a detailed description of new uses of current agents, and an integration of the available agents in clinical practice. A description of a detailed clinical approach provides clinical practitioners with the most up-to-date recommendations for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV) in various clinical settings.

CINV is one of the most feared treatment related toxicities. Patient surveys for the past thirty years consistently demonstrate patients’ perception of deterioration in quality of life due to chemotherapy treatments. The introduction of the antiemetics, serotonin 5-HT3 receptor antagonists and the neurokinin-1 receptor antagonists, have improved the control of chemotherapy-induced emesis, but the treatment of chemotherapy-induced nausea remains a significant clinical problem. Patients continue to have quality of life issues which prevent normal functioning during active treatment. New agents such as the second generation 5-HT3 receptor antagonist palonosetron and the new neuroknin-1 receptor antagonists rolapitant and netupitant are being introduced into clinical practice, and it is anticipated that these new agents will improve the control of CINV. Agents such as olanzapine (a FDA approved anti-psychotic), gabapentin (a FDA approved neuroleptic), and ginger (a food additive), which have been used primarily for other indications, are now being tested as potential, effective antiemetics. 

This work represents the first available comprehensive summary that details all new antiemetic agents and, particularly, their clinical role in treating patients; an important reference for practitioners seeking to improve the quality of life of patients undergoing chemotherapy.

Keywords

5-Hyroxytryptamine-3 Receptor Antagonists Anti-emetics Dexamethasone Gabapentin Multi-day Chemotherapy Neurokinin-1 Receptor Antagonists Olanzapine

Editors and affiliations

  • Rudolph M. Navari
    • 1
  1. 1.Indiana University School of MedicineSouth BendUSA

Bibliographic information

  • DOI https://doi.org/10.1007/978-3-319-27016-6
  • Copyright Information Springer International Publishing Switzerland 2016
  • Publisher Name Adis, Cham
  • eBook Packages Medicine
  • Print ISBN 978-3-319-27014-2
  • Online ISBN 978-3-319-27016-6
  • About this book